Revolution Medicines, Inc.
RVMD
Clasificación en acciones
#579
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Precio por acción
$196.16
Capitalización bursátil
$42.04B
Cambio (1 día)
7.69%
Cambio (1 año)
263.19%
País
US
Comercio Revolution Medicines, Inc. (RVMD)
Categoría
Healthcare
Ganancias de Revolution Medicines, Inc. (RVMD)
Ganancias en Jun 2026 TTM: $-1.77B
Secondo gli ultimi rapporti finanziari di Revolution Medicines, Inc., gli utili attuali della società sono $-1.77B. Nel 2023, la società ha registrato un utile di $-439.89M, una disminución en comparación con agli utili del 2022, che erano di $-249.13M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Revolution Medicines, Inc. desde 2017 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-1.77B | 194.30% |
| 2024 | $-600.85M | 36.59% |
| 2023 | $-439.89M | 76.57% |
| 2022 | $-249.13M | 33.16% |
| 2021 | $-187.09M | 72.39% |
| 2020 | $-108.53M | 108.56% |
| 2019 | $-52.04M | 24.52% |
| 2018 | $-41.79M | 34.25% |
| 2017 | $-31.13M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -398.31% |
US
|
|
| $-3.09B | 74.58% |
US
|
|
| $-4.02B | 127.12% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -210.31% |
NL
|
